Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 3Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 37Lung Neoplasms 20Carcinoma, Hepatocellular 18Breast Neoplasms 16Small Cell Lung Carcinoma 14Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 7Liver Neoplasms 7Neoplasm Metastasis 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Endometrial Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 5Carcinoma 5Biliary Tract Neoplasms 5Stomach Neoplasms 4Melanoma 4Colorectal Neoplasms 4Cholangiocarcinoma 4Prostatic Neoplasms 3Neoplasms by Site 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Uterine Cervical Neoplasms 2Turcot syndrome 2Thyroid Neoplasms 2Thoracic Neoplasms 2

Interventions

pembrolizumab 32Cisplatin 10Paclitaxel 8lenvatinib 6belzutifan 5Carboplatin 5Saline Solution 4Oxaliplatin 4Fluorouracil 4Pemetrexed 3Leucovorin 3Etoposide 3Docetaxel 3olaparib 2enfortumab vedotin 2durvalumab 2Radiotherapy 2Levoleucovorin 2Glucose 2Capecitabine 2Bevacizumab 2Albumin-Bound Paclitaxel 2130-nm albumin-bound paclitaxel 2zanidatamab 1tislelizumab 1sacituzumab govitecan 1liposomal doxorubicin 1enzalutamide 1balstilimab 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Parkinson Disease 4, Autosomal Dominant Lewy Body × durvalumab × Clear all
NCT04380636 2026-05-15

MK-7339-012

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
870 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05298423 2025-08-01

KEYVIBE-006

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
611 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡